Research Article

Prognostic Value of Homotypic Cell Internalization by Nonprofessional Phagocytic Cancer Cells

Manuela Schwegler, 1 Anna M. Wirsing, 1 Hannah M. Schenker, 1 Laura Ott, 1 Johannes M. Ries, 1 Maike Büttner-Herold, 2 Rainer Fietkau, 1 Florian Putz, 1 and Luitpold V. Distel 1

1Department of Radiation Oncology, University Hospital Erlangen, 91054 Erlangen, Germany
2Department of Pathology, University Hospital Erlangen, 91054 Erlangen, Germany

Correspondence should be addressed to Luitpold V. Distel; luitpold.distel@uk-erlangen.de

Received 13 February 2015; Accepted 17 June 2015

Academic Editor: Franco M. Buonaguro

Copyright © 2015 Manuela Schwegler et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. In this study, we investigated the prognostic role of homotypic tumor cell cannibalism in different cancer types.

Methods. The phenomenon of one cell being internalized into another, which we refer to as “cell-in-cell event,” was assessed in 416 cases from five head and neck cancer cohorts, as well as one anal and one rectal cancer cohort. The samples were processed into tissue microarrays and immunohistochemically stained for E-cadherin and cleaved caspase-3 to visualize cell membranes and apoptotic cell death. Results. Cell-in-cell events were found in all of the cohorts. The frequency ranged from 0.7 to 17.3 cell-in-cell events per mm². Hardly any apoptotic cells were found within the cell-in-cell structures, although apoptotic cell rates were about 1.6 to two times as high as cell-in-cell rates of the same tissue sample. High numbers of cell-in-cell events showed adverse effects on patients’ survival in the head and neck and in the rectal cancer cohorts. In multivariate analysis, high frequency was an adverse prognostic factor for overall survival in patients with head and neck cancer (p = 0.008). Conclusion. Cell-in-cell events were found to predict patient outcomes in various types of cancer better than apoptosis and proliferation and might therefore be used to guide treatment strategies.

1. Background

The mechanism by which a cell becomes internalized into another is the definition of the term “cell-in-cell formation” [1]. Cell-in-cell (CIC) formation includes the internalization of living lymphocytes into nonphagocytic cells (emperipoleisis), the homotypic and heterotypic phagocytosis-like uptake of living or dead cells, and the invasion of one tumor cell into the host cell (entosis). The definition also covers the fate of the included cells, which can undergo cell death, remain in the host cell, undertake cell division, or pass out of the cell. In this context the term cell cannibalism arose that describes the uptake of alive and dead tumor cells as well as of lymphocytes by tumor cells and is restricted to cancer cells [2]. Cannibalism was suggested as a marker of malignancy [3] and reported to provide an advantage for survival. Lugini et al. reported that cannibalistic malignant metastatic melanoma cells engulf autologous live CD8⁺ T-lymphocytes as a source of nutrients under starvation conditions [4]. Reports on homotypic cannibalism are conflicting, proposing a tumor-promoting and metastasis-protecting role. This discrepancy complicates the use of homotypic cannibalism as a prognostic factor [5–7] and highlights that further studies are necessary to shed light on this phenomenon and its impact on eventual cancer type-specific prognosis. Investigation on the phagocytic activity of cancer cells and normal fibroblasts may contribute to providing new insights into this issue [8, 9]. The use of in vivo experiments to identify the triggering factors and underlying mechanisms of cell cannibalism may facilitate a prognosis-relevant examination of CIC formation in association with specific proteins in tumor tissue sections.

Here, we present data on the prognostic relevance of CIC structures and their divergent effects on patient prognosis in
three different tumor entities. Additionally, the impact of CIC
rates was compared to those of apoptosis and proliferation.

2. Methods

2.1. Human Specimens. Cancer tissue samples from 416 patients
were evaluated for the presence of CIC structures. Patients
originated from seven different cohorts. (i) One cohort of
anal carcinomas (n = 23) and (ii) one rectal cancer cohort
(n = 83) were studied. Five head and neck squamous cell
carcinoma (HNSCC) cohorts were compared, including (iii)
an early disease, low-risk group (n = 62); (iv) an advanced
disease, high-risk group (n = 52); (v) cancer biopsies
with affected lymph nodes (n = 29); (vi) pretherapeutic
biopsies with posttherapeutic tumor resections (n = 35); and
(vii) pretherapeutic tumor resections of the central tumor
area and the invasion front (n = 143). All patients were
treated by definitive, adjuvant, or neoadjuvant radiotherapy
or radiochemotherapy. Patients characteristics are described
in Tables 1 and 2. Patient characteristics of five of the cohorts
were previously published [10–13]. All samples were pro-
cessed into tissue microarrays (TMAs) of 6.0–2.0 mm diameter
cores [14]. Clinical data were obtained from the Erlangen
Tumour Centre Database. All patients signed a “front door”
inform consent allowing collection of their tissue and
clinical data. The study was approved by the Ethics Review
Committee of the University Hospital Erlangen, Erlangen,
Germany.

2.2. Antibodies and Immunohistochemistry. Immunohisto-
chemistry was performed for detection of specific proteins
in tissue sections using several antibodies including Ki-67
(DakoCytomation, Hamburg, Germany), cleaved caspase-
3 (Cell Signaling, Danvers, MA, USA), E-cadherin (BD,
Heidelberg, Germany), CD68 (DakoCytomation), and Alexa
Fluor 488, 555, 594, and 647 conjugated secondary antibodies
(all from Invitrogen, Darmstadt, Germany).

Double staining was performed with Ki-67 and cleaved
caspase-3-specific antibodies. Briefly, sections were incu-
bated overnight with a cleaved caspase-3-specific antibody
and then a biotin-labeled secondary antibody. Biotin was
visualized using streptavidin-biotinylated alkaline phos-
phatase complex (DakoCytomation). Fast Red was used as
a chromogen. A double staining enhancer (Zymed, San
Francisco, California, USA) was used followed by an avidin
and biotin block (Avidin/Biotin Blocking Kit, Vector Labora-
tories, Peterborough, UK). Slides were incubated with Ki-67-
specific primary antibodies after application of a postblock
solution. Secondary antibodies covalently linked with an
AP-Polymer (ZytoChem-Plus, Berlin, Germany) were used
with Fast Blue (Sigma-Aldrich, Taufkirchen, Germany) as a
chromogen. E-cadherin labeling was performed on a Ventana
BenchMark Ultra stainer (Roche, Grenzach-Wyhlen, Ger-
many) using CCI buffer (Benchmark ULTRA CCI, Roche) for
antigen retrieval. Cell nuclei were stained with hematoxylin.

In a quadruple immunofluorescence approach, four anti-
gens were labeled successively in HNSCC tumor specimens.
Antigen retrieval was performed in a steam cooker (Biocarta
Europe, Hamburg, Germany) for 5 min at 120°C using a target
retrieval solution (pH 6) (TRS6, DakoCytomation) or 0.01 M
Na-citrate buffer (pH 6). Cells were stained with primary and
secondary antibodies, nuclei were counterstained with 4',6-
diamidino-2-phenylindole (DAPI) (Roche), and slides were
mounted with Vectashield medium (Vector Laboratories).

2.3. Imaging and Image Analysis. Stained TMAs were scanned
with a high throughput scanner (Mirax MIDI Scan, Zeiss,
Göttingen, Germany) equipped with a Plan-Apochromat
objective (20x; NA: 0.8, Zeiss) and a camera (Stingray F146C,
AVT, Stadtroda, Germany). Images were converted into TIF
format and each TMA spot was saved separately. CIC struc-
tures were counted using Biomas image processing software
(MSAB, Erlangen, Germany). A minimum of two TMA core
sections with tumor areas of 0.75 mm² was evaluated per
patient. Apoptotic cells, proliferating cells, and CIC structures
were counted in the same area. To achieve this, the E-cadherin
TMA spot was precisely aligned with Ki-67/cleaved caspase-
3 double-stained spot using the image analysis system. The
region of interest was selected in the E-cadherin spot and
transferred to the Ki-67/cleaved caspase-3 spot, and events
were counted.

2.4. Statistical Analysis. IBM SPSS Statistics version 19
was used. The Kolmogorov-Smirnov test and Lilliefors tests
were applied for testing normality. The local failure-free,
metastasis-free, and overall survival was calculated according
to Kaplan Meier. The log-rank test was used to compare
survival curves between subgroups of patients. Univariate
and multivariate regression analyses of overall survival were
performed using Cox’s proportional hazards model (Table 3,
additional file 2, Tables A2-A3 in Supplementary Material
available online at http://dx.doi.org/10.1155/2015/359392). The
proportional hazards assumption was tested through plotting
log-minus-log curves. p values < 0.05 were considered to be
significant.

3. Results

3.1. Study Groups. The frequency and prognostic relevance of
CIC structures in tumor tissue were investigated. A total of
416 tumor tissue samples from five cohorts of HNSCC and
one (i) anal and one (ii) rectal cancer cohort were analyzed
for the presence of CIC structures. The five HNSCC cohorts
consisted of the following: (iii) a low-risk, early disease,
treated by adjuvant radiochemotherapy (RCT); (iv) a high-
risk, advanced disease, treated by definitive radiotherapy
(RT) [10]; (v) metastatic disease, treated by adjuvant RT or
RCT [11]; (vi) no distant metastasis, treated by neoadjuvant
RCT [12]; and (vii) tumors treated by adjuvant RT or
RCT having tissue samples of the central tumor area and
the invasion front. The patients’ clinical and histological
characteristics are depicted in Tables 1 and 2. Overall survival
in the head and neck and rectal and anal cancer cohort were
60.3%, 75.0%, and 68.5% at 5 years, respectively. The median
follow-up in the head and neck and rectal and anal cancer
cohort were 4.6, 7.2, and 3.8 years, respectively. Median and
mean local failure-free, metastasis-free, and overall survival
time are presented in additional file 2, Table A1.
Table 1: Clinical characteristics of the head and neck squamous cell carcinoma cohorts.

<table>
<thead>
<tr>
<th></th>
<th>All HNSCC</th>
<th>Early disease</th>
<th>Advanced disease</th>
<th>Metastatic disease</th>
<th>Neoadjuvant RCT</th>
<th>Adjuvant RCT</th>
<th>Center/invasion front</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>321</td>
<td>62</td>
<td>52</td>
<td>29</td>
<td>35</td>
<td>143</td>
<td></td>
</tr>
<tr>
<td>Gender (n)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>274</td>
<td>(85.4)</td>
<td>51 (82.3)</td>
<td>43 (82.7)</td>
<td>28 (96.6)</td>
<td>32 (91.4)</td>
<td>120 (83.9)</td>
</tr>
<tr>
<td>Female</td>
<td>47</td>
<td>(14.6)</td>
<td>11 (17.7)</td>
<td>9 (17.3)</td>
<td>1 (3.4)</td>
<td>3 (8.6)</td>
<td>23 (16.1)</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (95% C.I.)</td>
<td>54.3</td>
<td>(53.9–55.7)</td>
<td>51.0</td>
<td>56.0</td>
<td>53.0</td>
<td>52.5</td>
<td>58.0 (56.2–59.2)</td>
</tr>
<tr>
<td>Loc. failure time (months)</td>
<td>50.0</td>
<td>(58.3–69.4)</td>
<td>67.0</td>
<td>(72.1–111)</td>
<td>42.0</td>
<td>(44.9–72.4)</td>
<td>51.0</td>
</tr>
<tr>
<td>Median (95% C.I.)</td>
<td>53.0</td>
<td>(61.7–73)</td>
<td>81.5</td>
<td>42.0</td>
<td>61.0</td>
<td>90.0</td>
<td>37.5 (37–48.3)</td>
</tr>
<tr>
<td>Overall survival time (months)</td>
<td>54.0</td>
<td>(63.5–74.6)</td>
<td>81.5</td>
<td>(82–121.7)</td>
<td>44.0</td>
<td>(47.6–74.2)</td>
<td>61.0</td>
</tr>
<tr>
<td>T stage (n)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>59 (18.4)</td>
<td>13 (21)</td>
<td>4 (6.6)</td>
<td>7 (24.1)</td>
<td>3 (8.6)</td>
<td>36 (25.2)</td>
<td>38 (26.6)</td>
</tr>
<tr>
<td>T2</td>
<td>105 (32.7)</td>
<td>30 (48.4)</td>
<td>2 (3.8)</td>
<td>8 (27.6)</td>
<td>9 (25.7)</td>
<td>56 (39.2)</td>
<td>29 (20.3)</td>
</tr>
<tr>
<td>T3</td>
<td>78 (24.3)</td>
<td>14 (22.6)</td>
<td>25 (48.1)</td>
<td>6 (20.7)</td>
<td>6 (17.1)</td>
<td>27 (18.9)</td>
<td>27 (18.9)</td>
</tr>
<tr>
<td>T4</td>
<td>79 (24.6)</td>
<td>5 (8.1)</td>
<td>25 (48.1)</td>
<td>8 (27.6)</td>
<td>17 (48.6)</td>
<td>24 (16.8)</td>
<td>19 (13.5)</td>
</tr>
<tr>
<td>N stage (n)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>68 (21.2)</td>
<td>23 (37.1)</td>
<td>5 (9.6)</td>
<td>0 (0)</td>
<td>7 (20.0)</td>
<td>38 (26.6)</td>
<td>38 (26.6)</td>
</tr>
<tr>
<td>N1</td>
<td>55 (17)</td>
<td>17 (27.4)</td>
<td>4 (7.7)</td>
<td>4 (13.8)</td>
<td>2 (57)</td>
<td>29 (20.3)</td>
<td>29 (20.3)</td>
</tr>
<tr>
<td>N2</td>
<td>186 (57.9)</td>
<td>22 (35.5)</td>
<td>41 (78.8)</td>
<td>23 (79.3)</td>
<td>25 (71.4)</td>
<td>69 (48.3)</td>
<td>69 (48.3)</td>
</tr>
<tr>
<td>N3</td>
<td>12 (3.7)</td>
<td>0 (0)</td>
<td>2 (3.8)</td>
<td>2 (6.9)</td>
<td>1 (2.9)</td>
<td>7 (4.9)</td>
<td>7 (4.9)</td>
</tr>
<tr>
<td>M stage (n)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>237 (73.8)</td>
<td>62 (100.0)</td>
<td>39 (75.0)</td>
<td>6 (20.7)</td>
<td>32 (91.4)</td>
<td>98 (68.5)</td>
<td>98 (68.5)</td>
</tr>
<tr>
<td>M1</td>
<td>84 (26.2)</td>
<td>0 (0)</td>
<td>13 (25.0)</td>
<td>23 (79.3)</td>
<td>3 (8.6)</td>
<td>45 (31.5)</td>
<td>45 (31.5)</td>
</tr>
<tr>
<td>Grading (n)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G1/2</td>
<td>176 (54.8)</td>
<td>37 (59.7)</td>
<td>37 (71.2)</td>
<td>15 (51.7)</td>
<td>27 (77.1)</td>
<td>60 (42)</td>
<td>60 (42)</td>
</tr>
<tr>
<td>G3/4</td>
<td>145 (45.2)</td>
<td>25 (40.3)</td>
<td>15 (28.8)</td>
<td>14 (48.3)</td>
<td>8 (22.9)</td>
<td>83 (58)</td>
<td>83 (58)</td>
</tr>
<tr>
<td>UICC97 (n)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>15 (4.7)</td>
<td>6 (9.7)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (2.9)</td>
<td>8 (5.6)</td>
<td>8 (5.6)</td>
</tr>
<tr>
<td>2</td>
<td>30 (9.3)</td>
<td>13 (21)</td>
<td>1 (3.4)</td>
<td>2 (57)</td>
<td>2 (57)</td>
<td>14 (9.8)</td>
<td>14 (9.8)</td>
</tr>
<tr>
<td>3</td>
<td>61 (19)</td>
<td>17 (27.4)</td>
<td>2 (3.8)</td>
<td>2 (6.9)</td>
<td>2 (57)</td>
<td>33 (23.1)</td>
<td>33 (23.1)</td>
</tr>
<tr>
<td>4</td>
<td>215 (67)</td>
<td>26 (14.9)</td>
<td>45 (86.5)</td>
<td>26 (89.7)</td>
<td>30 (85.7)</td>
<td>88 (61.5)</td>
<td>88 (61.5)</td>
</tr>
</tbody>
</table>

Values behind the first bracket are relative values within the subcohort and values behind the second bracket are relative values of the total cohort. Confidence interval: C.I.
Table 2: Clinical characteristics of the rectal and anal cancer cohorts.

<table>
<thead>
<tr>
<th></th>
<th>Rectal cancer, clinical</th>
<th>Rectal cancer, pathological</th>
<th>Anal cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>83</td>
<td>83</td>
<td>23</td>
</tr>
<tr>
<td>Male</td>
<td>59 (71.1)</td>
<td>9 (39.1)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>24 (28.9)</td>
<td>14 (60.9)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (95% C.I.)</td>
<td>64.0 (59.7–65.2)</td>
<td>59.0 (48.7–64.2)</td>
<td></td>
</tr>
<tr>
<td>Local failure time (months)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (95% C.I.)</td>
<td>39.0 (35.7–44.1)</td>
<td>71.0 (53.3–98.8)</td>
<td></td>
</tr>
<tr>
<td>Time to metastatic disease (months)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (95% C.I.)</td>
<td>38.0 (29.9–40.5)</td>
<td>82.0 (62–113.5)</td>
<td></td>
</tr>
<tr>
<td>Overall survival time (months)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (95% C.I.)</td>
<td>44.0 (41.9–48.6)</td>
<td>86.5 (65.9–115.6)</td>
<td></td>
</tr>
<tr>
<td>T stage (n)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T0</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>T1</td>
<td>0 (0)</td>
<td>2 (2.4)</td>
<td>1 (4.3)</td>
</tr>
<tr>
<td>T2</td>
<td>7 (8.4)</td>
<td>25 (30.1)</td>
<td>13 (56.5)</td>
</tr>
<tr>
<td>T3</td>
<td>64 (77.1)</td>
<td>32 (38.6)</td>
<td>7 (30.4)</td>
</tr>
<tr>
<td>T4</td>
<td>12 (14.5)</td>
<td>13 (15.7)</td>
<td>2 (8.7)</td>
</tr>
<tr>
<td>N stage (n)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>18 (21.7)</td>
<td>53 (63.9)</td>
<td>10 (43.5)</td>
</tr>
<tr>
<td>N1</td>
<td>52 (62.7)</td>
<td>30 (36.1)</td>
<td>5 (21.7)</td>
</tr>
<tr>
<td>N2</td>
<td>13 (15.7)</td>
<td>0 (0.0)</td>
<td>8 (34.8)</td>
</tr>
<tr>
<td>M stage (n)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>53 (63.9)</td>
<td>—</td>
<td>20 (87)</td>
</tr>
<tr>
<td>M1</td>
<td>30 (36.1)</td>
<td>—</td>
<td>3 (13)</td>
</tr>
<tr>
<td>Grading (n)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G1/2</td>
<td>73 (88.0)</td>
<td>—</td>
<td>16 (69.6)</td>
</tr>
<tr>
<td>G3/4</td>
<td>10 (12.0)</td>
<td>—</td>
<td>7 (30.4)</td>
</tr>
<tr>
<td>UICC97 (n)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>22 (26.5)</td>
<td>3 (13)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>28 (33.7)</td>
<td>7 (30.4)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>21 (25.3)</td>
<td>13 (56.5)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>12 (14.5)</td>
<td>0 (0)</td>
<td></td>
</tr>
</tbody>
</table>

3.2. Criteria of CIC Structures. All tumor tissues were processed into TMAs and were stained for the adhesion molecule E-cadherin to visualize cell membranes. Nuclei were counterstained with hematoxylin (Figure 1(a)). Stained TMA spots were analyzed for the presence of CIC events per mm² using an image analysis system. Three criteria were used to define homotypic CICs: total encirclement of the inner cell by the host cell membrane, a semilunar host cell nucleus, and a round shape of the inner cell (Figure 1(b)).

3.3. CIC Structures Are Found in Various Tumor Tissues with Varying Frequencies. CIC structures were found in all of the cancer cohorts. The average frequency ranged from 0.7 CICs/mm² in the (iii) low-risk, early disease HNSCC to 17.3 CICs/mm² in the (ii) rectal cancer group (Figure 1(c)). The percentage of CIC-positive cancer tissues varied from 25.0% in the (vi) posttherapeutic HNSCC collection to 95.7% in the (i) anal cancer cohort (Figure 1(d) (A)–(E)). The pretherapeutic biopsies from the anal cancer cohort showed a high frequency of CIC-positive samples, with an average frequency of 10.7 CICs/mm². However, the highest single values of up to 200 CICs/mm² were observed in the (ii) posttherapeutic rectal cancer cohort.

In HNSCC tumor samples, we grouped the patients cohorts according to low- and high-risk characteristics and treatment modalities for separate analyses and comparison. We found that (iv) high-risk, inoperable patients with advanced disease had significantly more CIC than (iii) low-risk patients with early disease (Figures 1(c) and 1(d) (B)). In (v) lymph nodes, the average CIC numbers were significantly lower than in the corresponding primary tumors, while the number of CIC-positive patients differed only slightly (Figures 1(c) and 1(d) (C)). In a HNSCC cohort with (vi) pretherapeutic biopsy and tumor resections six weeks after RCT, both the frequency of CIC-positive patients and the average CIC number decreased significantly (Figures 1(c) and 1(d) (D)). We also compared CIC numbers in the (vii) central tumor area and at the invasive front. In the central tumor
<table>
<thead>
<tr>
<th>Variable</th>
<th>HNSSC central tumor area; ( n = 143 )</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hazard ratio</td>
<td>95% C.I.</td>
<td>( p )</td>
</tr>
<tr>
<td>Age, years (younger than 58 years ( n = 72 ) versus older than 58 years ( n = 71 ))</td>
<td>1.853</td>
<td>1.007–3.41</td>
<td>0.048</td>
</tr>
<tr>
<td>Gender (male ( n = 120 ) versus female ( n = 23 ))</td>
<td>1.275</td>
<td>0.566–2.871</td>
<td>0.558</td>
</tr>
<tr>
<td>T category (T1/T2 ( n = 92 ) versus T3/T4 ( n = 51 ))</td>
<td>0.748</td>
<td>0.36–1.554</td>
<td>0.436</td>
</tr>
<tr>
<td>N category (N0 ( n = 38 ) versus N+ ( n = 105 ))</td>
<td>1.080</td>
<td>0.333–3.5</td>
<td>0.899</td>
</tr>
<tr>
<td>M-category (M0 ( n = 98 ) versus M+ ( n = 45 ))</td>
<td>8.094</td>
<td>1.59–41.2</td>
<td>0.012</td>
</tr>
<tr>
<td>Stage (UICC I ( n = 22 ) versus UICC II and higher ( n = 121 ))</td>
<td>0.971</td>
<td>0.309–3.053</td>
<td>0.960</td>
</tr>
<tr>
<td>Grade (1+2 ( n = 60 ) versus 3+4 ( n = 83 ))</td>
<td>0.987</td>
<td>0.526–1.851</td>
<td>0.967</td>
</tr>
<tr>
<td>CIC (0/mm(^2) ( n = 74 ) versus &gt;0/mm(^2) ( n = 69 ))</td>
<td>2.555</td>
<td>1.334–4.894</td>
<td>0.005</td>
</tr>
<tr>
<td>Apoptotic cells (&lt;9.5/mm(^2) ( n = 71 ) versus ≥9.5/mm(^2) ( n = 72 ))</td>
<td>1.037</td>
<td>0.329–3.266</td>
<td>0.950</td>
</tr>
<tr>
<td>Proliferating cells (&lt;122/mm(^2) ( n = 71 ) versus ≥122/mm(^2) ( n = 72 ))</td>
<td>0.689</td>
<td>0.358–1.325</td>
<td>0.264</td>
</tr>
</tbody>
</table>
(a) 

(b) 

Tissue | n = 23 | 83 | 62 | 52 | 29 | 29 | 35 | 32 | 143 | 102 
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- 
with CIC (%) = 95.7 72.2 67.7 69.2 82.6 75.9 80.0 25.0 49.7 27.5 

Cell-in-cell (mm$^2$) 

(c) 

Figure 1: Continued.
Figure 1: Continued.

(i) Anal cancer

CIC\(^+\): 95.7%

(ii) Rectal cancer

CIC\(^+\): 72.2%

(iii) Low-risk early disease

CIC\(^+\): 67.7%

(iv) High-risk advanced disease

CIC\(^+\): 69.2%

(v) Tumor

CIC\(^+\): 82.6%

(v) Lymph node

CIC\(^+\): 75.9%
Figure 1: Cell-in-cell structures are found in different tumor tissues. (a) Representative image of an E-cadherin-labeled head and neck squamous cell carcinoma tissue microarray spot with numerous CIC structures and magnifications of indicated regions. (b) Representative images of E-cadherin-labeled head and neck cancer CIC structures. (c) Frequency of CIC structures in different cancer types. (d) Comparative frequency of CIC (A) in the tumor tissue of rectal and anal cancer patients, (B) in low-risk and high-risk HNSCC patients, (C) in the primary tumor of HNSCC tumors and the affected regional lymph nodes, (D) before and after neoadjuvant radiochemotherapy, and (E) in the central tumor area and invasive front of HNSCC. R(C)T: radiochemotherapy or radiotherapy.

area, more samples were CIC-positive and the overall average value of CIC structures was higher than in the invasive front (Figures 1(c) and 1(d) (E)).

3.4. CIC Rate Compared to Apoptotic Cell Death and Proliferation. We then compared CIC frequency to apoptotic cell death and proliferation by quantifying apoptotic and proliferating cells in HNSCC samples stained for cleaved caspase-3 and Ki-67. In total, we studied 143 central tumor samples and 102 invasive front samples. Compared to invasive front samples, significantly more CIC structures and apoptotic cells were identified in samples from cancer centers. In the central tumor area, the portion of apoptotic cells was 1.6 times higher than that of CIC structures, and the number of apoptotic cells in the invasive front was two times higher (Figures 2(a) and 2(b)). The proportion of proliferating cells was much higher than that of CIC and apoptosis, with similar frequencies in the central tumor area and the invasive front (Figures 2(a) and 2(c)).

3.5. CIC Rate and Cell Death Events in Tumor Sections. We were particularly interested in whether the inner cells of
Figure 2: Apoptotic and proliferating cell rates. (a) CIC events, apoptotic cells, and proliferating cells in the central tumor area and invasive front of HNSCC. Frequency of (b) apoptotic and (c) proliferating cells in the central tumor area compared to the invasive front of individual HNSCC patients.
CIC structures in tumor tissue were apoptotic. Thus, we stained the HNSCC tumor samples with cleaved caspase-3 to determine whether CIC structures in tumor tissue sections contained apoptotic cells. We counted 572 CIC events and found three cleaved caspase-3-positive cells; thus 99.5% of CIC structures were negative for cleaved caspase-3 (Figure 3(a)).

To determine whether there is a relationship between the frequency of CIC formation and apoptotic cells, we correlated both events in the pre- and posttherapeutic tissue samples from central tumor areas and invasion fronts. There was no correlation between these events, indicating that high numbers of apoptotic cells do not promote CIC formation (Figures 3(b) and 3(c)).

Additionally, we used multicolor immunofluorescence imaging of anal and HNSCC cancer in order to stain the tissue with DAPI, E-cadherin, cleaved caspase-3, Ki-67, and the phagocytic marker CD68. A recent report on homotypic cell cannibalism in pancreatic adenocarcinoma suggested ectopic expression of the scavenger receptor gene CD68 as a marker of cannibalistic cells in pancreatic adenocarcinoma [7]. Our histological study did not reveal expression of CD68 indicating that this molecule is not necessary for CIC formation in these tissues. We visualized rare CIC structures (green arrows) with inner apoptotic cells (red arrows), high numbers of not-engulfed Ki-67-positive proliferating cells (yellow arrow), and CD68-positive cells (orange arrows) that were presumably macrophages (Figure 3(d), additional file 1, Figure A1).

3.6. CIC Rates as Prognostic Factor for Different Tumor Entities. In total, 23 anal cancer patients, 83 rectal cancer patients, and 234 HNSCC patients were included in this analysis. Kaplan-Meier plot analysis was based on the elapsed time from the date of diagnosis, and this method revealed that more than 10 CICs/mm² had a positive impact on local failure-free survival for anal cancer (p = 0.007). The correlation for metastasis-free, tumor-specific survival (additional file 1, Figure A2) and overall survival was weaker. By contrast, either low numbers or the absence of CIC structures had a beneficial prognostic value in rectal cancer and HNSCC. In these cohorts, low CIC rates were associated with longer local failure-free and metastasis-free survival (p = 0.032, for rectal cancer). Low numbers or the absence of CIC structures was significantly correlated to an improved overall survival in HNSCC (p = 0.005) (Figure 4).

A multivariate analysis of the HNSCC adjuvant therapy subgroup with samples of the central tumor area was performed. Age, M-category, CIC/mm², and proliferating cells/mm² were included. Only CIC/mm² and M-category were independent significant variables with impact on overall survival (Table 2). Neither apoptotic rates nor proliferating cells had an impact on overall survival. The five HNSCC cohorts were grouped and a multivariate analysis was performed; for those cases all clinical data, patient’s characteristics, and immunohistological data were available. 234 patients were included and gender, M-category, grading, and CIC/mm² were analyzed in a multivariate way. Again only CIC/mm² and M-category were independent significant variables with impact on overall survival (additional file 2, Table A2). In multivariate analysis of rectal cancer patients distance of tumor from anal verge, grading, and CIC/mm² were included. Only grading was an independent significant variable with impact on overall survival (additional file 2, Table A3).

4. Discussion

4.1. CIC Frequency in Tissue Correlates with Patient Outcomes. CIC events were observed in all of the cohorts, but the number of CIC-positive patients and the CIC rates vary considerably, depending on the cancer type, stage, previous therapeutic intervention, and localization of CIC events within the tumor. Compared to apoptotic cell rates, CIC rates are half to two-thirds as frequent. Though CICs are frequent events they have been nearly completely disregarded in the last 100 years [15]. We studied the possible correlation between CIC structures found in tumor tissues and patients’ prognosis and confirmed that engulfed tumor cells in HNSCC and rectal and anal carcinoma tissues have a clear impact on the prognosis of these patients. In the anal cancer cohort, high numbers of CIC events led to an improved prognosis, whereas, in the HNSCC and rectal cancer cohorts, low numbers were associated with a good prognosis. Previously, a relationship between the occurrence of homotypic CIC structures and low risk for metastasis was observed in pancreatic adenocarcinoma patients [7]. In contrast, several studies have proposed a relationship between poor prognosis and the presence of homotypic cannibalism in breast carcinoma [6], bladder cancer [16], and medulloblastoma [5], as well as the presence of heterotypic cannibalism in gastric carcinoma [17]. Consistent with these heterogeneous studies, our results indicate that existence of CIC structures affects patient outcomes in different ways. The discrepancy observed in the correlation of CIC frequency and patient outcomes in different tumor entities might be explained by tissue and cell type-specific properties regarding tumor-specific metastatic potential and immune cell infiltration.

It was shown that homotypic CIC structures normally undergo cell death [7] regardless of whether alive cells or dead cells are internalized [4, 18]. Therefore, CIC seems to be a kind of cell death. However, the Nomenclature Committee on Cell Death (NCCD) demands the approval of CIC to be degraded within the cell as a result of homotypic interactions and that it should not be dependent on apoptotic cell [19]. Thus, we compared the frequency of apoptotic cells to CIC rates. We found CIC rates, which were half to two-thirds as frequent as apoptotic rates. However, only very rarely the engulfed cells were apoptotic and there was no correlation between the frequency of apoptotic and CIC rates. We hypothesize that the conditions of the NCCD are met. We would speculate that the engulfed cells were alive and matrix-deprived cells similar to metastatic cells and were phagocytized by cancer cells. Further, after engulfment cells lacked the chance to develop an apoptotic phenotype due to internalization and metabolic degradation.
Figure 3: Continued.
Alternatively, it is possible that necrotic dying cells were phagocytized. Nevertheless, CIC frequency was an independent prognostic factor in multivariate analyses of the HNSCC cohorts, whereas apoptotic and proliferating rates did not reach a comparable impact. Maybe CICs have a similar high importance in prognosis as apoptosis and proliferation. Furthermore it could be speculated that CIC structure formation impacts tumor patient outcomes by elimination.
Figure 4: Kaplan-Meier analyses. (a) Kaplan-Meier curves depicting anal and (b) rectal cancer patients with fewer than 10 CIC structures per 10 mm$^2$ (blue solid lines) and with equal or more than 10 CIC structures per 10 mm$^2$ (green dotted lines). HNSCC patients with CIC structures (green dotted lines) and without CIC structures (blue solid lines) (c) in the central tumor area and (d) from all five HNSCC patient cohorts; from those patients the clinical data, patients’ characteristics, and immunohistological data were completely available.
of detached cells that might form metastasis or suppression of the immune response by prohibition of emanation of immunogenic signals by nonapoptotic dying cells.

5. Conclusion

Our histological analyses showed that tumor cells containing incorporated, nonapoptotic tumor cells are commonly observed in many tumor tissue samples. Furthermore, we demonstrated that CIC structures correspond with clinical outcome depending on the cancer type and may have opposing effects on prognosis. CIC frequency is a valuable independent prognostic factor which should be considered in the same way as proliferation or apoptosis. Future work should also focus on functional studies in order to gain more insights into the mechanisms of CIC formation and to evaluate its potential value as a prognostic marker in other types of cancer.

Conflict of Interests

The authors declare that there have no conflict of interests in the research.

Acknowledgments

The authors thank the Tumour Centre at the Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany, for providing them with patient data. They especially thank Christa Winkelmann for excellent technical assistance. The authors thank Carol Geppert for assistance with the “Whole Slide Imaging.”

References
